AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yardley, V.
Right arrow Articles by Oldfield, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yardley, V.
Right arrow Articles by Oldfield, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2002, p. 929-931, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.929-931.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vivo Activities of Farnesyl Pyrophosphate Synthase Inhibitors against Leishmania donovani and Toxoplasma gondii

Vanessa Yardley,1 Anis A. Khan,2,{dagger} Michael B. Martin,3 Teri R. Slifer,2 Fausto G. Araujo,2 Silvia N. J. Moreno,4 Roberto Docampo,4 Simon L. Croft,1 and Eric Oldfield3,5*

Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom,1 Department of Infectious Diseases, Palo Alto Medical Foundation, Palo Alto, California 94301 ,2 Department of Chemistry,3 Department of Biophysics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801,5 Laboratory of Molecular Parasitology, Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois 618024

Received 27 August 2001/ Returned for modification 1 October 2001/ Accepted 6 December 2001

The in vivo activities of three bisphosphonates were determined against Leishmania donovani and Toxoplasma gondii. Alendronate was essentially inactive against both parasites. Pamidronate was active against L. donovani by intravenous administration. Risedronate had a 50% effective dosage of five 2.6-mg/kg of body weight intraperitoneal doses against L. donovani-infected mice but was less effective against T. gondii-infected mice.

* Corresponding author. Mailing address: Department of Chemistry, University of Illinois at Urbana-Champaign, 600 South Mathews Ave., Urbana, IL 61801. Phone: (217) 333-3374. Fax: (217) 244-0997. E-mail: eo{at}chad.scs.uiuc.edu.

{dagger} Present address: Global Metabolism and Investigative Sciences, Pharmacia Corporation, 4901 Searle Pkwy., Skokie, IL 60077.

Antimicrobial Agents and Chemotherapy, March 2002, p. 929-931, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.929-931.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2002 by the American Society for Microbiology. All rights reserved.